Clinical Trial Update: A Study to Compare LY2963016 to Lantus After a Single Dose to Participants With Type 1 Diabetes Mellitus [Phase 1]

View source ↗

Summary

Phase 1 trial comparing LY2963016 with Lantus (insulin glargine) after a single dose in people with type 1 diabetes; results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• LY2963016 (insulin glargine)
• Lantus (insulin glargine)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Diabetes Mellitus, Type 1 | Phase 1 | Status: COMPLETED | Results posted: 2014-10-07